NOVARTIS AG NAMENS-AKTIEN SF 0,5
NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
904278
|
13/11/2024 23:00:02
|
Chg.
-0.540
|
Volume |
Bid23:00:02 |
Ask23:00:02 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
97.900EUR
|
-0.55%
|
-
Turnover: - |
97.900Bid Size: - |
98.740Ask Size: - |
224.7 bill.EUR |
- |
- |
Business description
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
Management board & Supervisory board
| CEO |
| Vasant Narasimhan, M.D. |
| Management board |
| Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall, Patrick Horber |
| Supervisory board |
| Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young, Patrice Bula |
Company data
| Name: |
Novartis AG |
| Address: |
Lichtstrasse 35,CH-4002 Basel |
| Phone: |
+41-61-324-1111 |
| Fax: |
+41-61-324-8001 |
| E-mail: |
-
|
| Internet: |
www.novartis.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
86.85% |
| IPO date: |
07/03/1996 |
Company calendar
|
CW 5 | 31/01/2025
4th Quarter/Annual Report
|
|
CW 10 | 07/03/2025
General Shareholder Meeting
|
